ホーム>>Signaling Pathways>> Cell Cycle/Checkpoint>> Microtubule/Tubulin>>Rosabulin (STA 5312)

Rosabulin (STA 5312)

カタログ番号GC33169

ロザブリン (STA 5312) (STA 5312) は、微小管の集合を阻害する強力な経口活性微小管阻害剤です。ロザブリン (STA 5312) には、広範囲の抗腫瘍活性があります。

Products are for research use only. Not for human use. We do not sell to patients.

Rosabulin (STA 5312) 化学構造

Cas No.: 501948-05-6

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$293.00
在庫あり
5mg
$266.00
在庫あり
10mg
$420.00
在庫あり
25mg
$805.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Rosabulin is a potent microtubule inhibitor, with anti-cancer activities.

Rosabulin demonstrates substantial anti-proliferative activity against a wide range of cancer cell linesin vitro, with IC50 values extending down into the nanomolar range. Rosabulin is inhibition of microtubule assembly and subsequent arrest of the cell cycle. Rosabulin is active against several tumor cell lines that express moderate to high levels of P-glycoprotein (Pgp), including lines insensitive to Taxol, Vincristine, and Adriamycin in which Pgp activity is a major contributor to the MDR phenotype[1].

Rosabulin has shown in vivo activity in several murine tumors as well as human tumor xenograft models, including drug resistant tumors[1].

[1]. Keizo Koya, et al. STA-5312, a novel tubulin inhibitor, demonstrates the anti-cancer activity against chemotherapy-resistant cancers. Proc Amer Assoc Cancer Res, Volume 45, 2004

レビュー

Review for Rosabulin (STA 5312)

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Rosabulin (STA 5312)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.